|
gptkbp:instanceOf
|
gptkb:drug
anticonvulsant
|
|
gptkbp:affects
|
central nervous system
|
|
gptkbp:approvalYear
|
1953
|
|
gptkbp:approvedBy
|
gptkb:United_States
|
|
gptkbp:ATCCode
|
gptkb:N03AB02
|
|
gptkbp:bioavailability
|
70–100%
|
|
gptkbp:brand
|
gptkb:Epanutin
gptkb:Dilantin
|
|
gptkbp:CASNumber
|
57-41-0
|
|
gptkbp:category
|
hydantoin derivative
|
|
gptkbp:chemicalFormula
|
C15H12N2O2
|
|
gptkbp:contraindication
|
heart block
hypersensitivity to phenytoin
sinus bradycardia
|
|
gptkbp:cost
|
low
|
|
gptkbp:discoveredBy
|
gptkb:H._Houston_Merritt
gptkb:Tracy_Putnam
|
|
gptkbp:discoveredIn
|
1938
|
|
gptkbp:drugInteraction
|
gptkb:isoniazid
gptkb:warfarin
cimetidine
oral contraceptives
|
|
gptkbp:eliminationHalfLife
|
22 hours
|
|
gptkbp:excretion
|
urine
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
phenytoin
|
|
gptkbp:IUPACName
|
5,5-diphenylimidazolidine-2,4-dione
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
blocks voltage-gated sodium channels
|
|
gptkbp:MedlinePlusID
|
a682022
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
252.27 g/mol
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:proteinBinding
|
90%
|
|
gptkbp:PubChem_CID
|
1775
|
|
gptkbp:riskFactor
|
gptkb:toxic_epidermal_necrolysis
gptkb:Stevens-Johnson_syndrome
teratogenicity
drug-induced lupus
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
|
|
gptkbp:sideEffect
|
nystagmus
rash
drowsiness
ataxia
gingival hyperplasia
|
|
gptkbp:synonym
|
gptkb:diphenylhydantoin
|
|
gptkbp:UNII
|
6158TKW0C5
|
|
gptkbp:usedFor
|
epilepsy
seizure prevention
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:CYP2C9
gptkb:warfarin
gptkb:CYP3_family
gptkb:CYP3A4
gptkb:Class_I_antiarrhythmic_drugs
gptkb:Tegretol
|
|
gptkbp:bfsLayer
|
5
|